In the published article, there was an error in affiliations 3 and 4. Instead of “3. Division of Clinical Research, Department of Medical Research and Division of Medical Oncology, Center for Immuno-oncology, Taipei, Taiwan, 4 Department of Oncology, Taipei Veterans General Hospital and National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan”, it should be “3. Division of Clinical Research, Department of Medical Research and Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, 4. National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan”.
In the published article, an author name was incorrectly written as “Sean M.N. Wong”. The correct spelling is “Natalie S.M. Wong”.
In the published article, there was an error in the Funding statement. An acknowledgement was missed. The correct Funding statement appears below.
Funding
This work was supported in part by the Chang Gung Memorial Hospital CMRPG3J0971~3 CORPG3J0251~3. We thank to Zai Lab (Taiwan) Limited for the educational grant to Taiwan Society of Molecular Medicine. The funder Zai Lab (Taiwan) was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
ripretinib, GIST, compassionate use, advanced, metastatic
Citation
Lin L-C, Huang W-K, Yen C-C, Yang C-Y, Sung M-T, Wong NSM, Chua DTT, Lee SWM, Chen J-S and Yeh C-N (2022) Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience. Front. Oncol. 12:1028118. doi: 10.3389/fonc.2022.1028118
Received
01 September 2022
Accepted
06 September 2022
Published
13 October 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
12 - 2022
Updates
Copyright
© 2022 Lin, Huang, Yen, Yang, Sung, Wong, Chua, Lee, Chen and Yeh.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chun-Nan Yeh, yehchunnan@gmail.com
†These authors have contributed equally to this work
This article was submitted to Gastrointestinal Cancers: Gastric and Esophageal Cancers, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.